Glutamate receptor dysfunction and drug targets across models of autism spectrum disorders

Pharmacology Biochemistry and Behavior

Volumn 100, Issue 4, 2012, Pages 850-854

  Carlson, Greg C ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Kainate; mGluR; MPEP; Neuroligin; NMDA; PSD 95; SHANK

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; AMPA RECEPTOR; FRAGILE X MENTAL RETARDATION PROTEIN; GLUTAMATE RECEPTOR 5; GLUTAMATE RECEPTOR 6; KAINIC ACID RECEPTOR; METHYL CPG BINDING PROTEIN 2; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUREXIN; NEUROLIGIN; NEUROLIGIN 1; POSTSYNAPTIC DENSITY PROTEIN 95;

ANXIETY; AUTISM; CHILD; DISEASE MODEL; DROSOPHILA; DRUG TARGETING; EXCITATORY POSTSYNAPTIC POTENTIAL; FRAGILE X SYNDROME; GENETIC CODE; GENETIC MODEL; HUMAN; INSULIN RESISTANCE; NERVE CELL PLASTICITY; NERVE CELL STIMULATION; NONHUMAN; PATHOPHYSIOLOGY; PREDICTIVE VALIDITY; PRIORITY JOURNAL; REVIEW; RNA TRANSLATION; SYNAPSE;

EID: 84855541549     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2011.02.003     Document Type: Article

References (80)

1. Akhondzadeh S, Tajdar H, Mohammadi MR, Mohammadi M, Nouroozinejad GH, Shabstari OL, et al. A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder. Child Psychiatry Hum Dev 2008;39:237-45. (Pubitemid 351839896)
2. Bardoni B, Mandel JL. Advances in understanding of fragile X pathogenesis and FMRP function, and in identification of X linked mental retardation genes. Curr Opin Genet Dev 2002;12:284-93. (Pubitemid 34663761)
3. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci 2004;27:370-7. (Pubitemid 38829251)
4. Berkel S, Marshall CR, Weiss B, Howe J, Roeth R, Moog U, et al. Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardation. Nat Genet 2010;42:489-91.
5. Betancur C, Sakurai T, Buxbaum JD. The emerging role of synaptic cell-adhesion pathways in the pathogenesis of autism spectrum disorders. Trends Neurosci 2009;32:402-12.
6. Blundell J, Blaiss CA, Etherton MR, Espinosa F, Tabuchi K, Walz C, et al. Neuroligin-1 deletion results in impaired spatial memory and increased repetitive behavior. J Neurosci 2010;30:2115-29.
7. Bozdagi O, Sakurai T, Papapetrou D, Wang X, Dickstein DL, Takahashi N, et al. Haploinsufficiency of the autism-associated Shank3 gene leads to deficits in synaptic function, social interaction, and social communication. Mol Autism 2010;1:15.
8. Brodkin ES. Social behavior phenotypes in fragile X syndrome, autism, and the Fmr1 knockout mouse: theoretical comment on McNaughton et al. (2008). Behav Neurosci 2008;122:483-9. (Pubitemid 351672340)
9. Bruneau EG, Esteban JA, Akaaboune M. Receptor-associated proteins and synaptic plasticity. FASEB J 2009;23:679-88.
10. Chen RZ, Akbarian S, Tudor M, Jaenisch R. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet 2001;27:327-31. (Pubitemid 32201857)
11. Chez MG, Burton Q, Dowling T, Chang M, Khanna P, Kramer C. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol 2007;22:574-9. (Pubitemid 46951501)
12. Crawley JN. Mouse behavioral assays relevant to the symptoms of autism. Brain Pathol 2007;17:448-59. (Pubitemid 47537604)
13. Dahlhaus R, El-Husseini A. Altered neuroligin expression is involved in social deficits in a mouse model of the fragile X syndrome. Behav Brain Res 2010;208:96-105.
14. de Vrij FM, Levenga J, van der Linde HC, Koekkoek SK, De Zeeuw CI, Nelson DL, et al. Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis 2008;31:127-32. (Pubitemid 351822560)
15. den Broeder MJ, van der Linde H, Brouwer JR, Oostra BA, Willemsen R, Ketting RF. Generation and characterization of FMR1 knockout zebrafish. PLoS ONE 2009;4:e7910.
16. Dolen G, Bear MF. Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome. J Physiol 2008;586:1503-8. (Pubitemid 351404955)
17. Dolen G, Carpenter RL, Ocain TD, Bear MF. Mechanism-based approaches to treating fragile X. Pharmacol Ther 2010;127:78-93.
18. Duncan GE, Moy SS, Perez A, Eddy DM, Zinzow WM, Lieberman JA, et al. Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behav Brain Res 2004;153:507-19. (Pubitemid 38953128)
19. Eadie BD, Cushman J, Kannangara TS, Fanselow MS, Christie BR. NMDA receptor hypofunction in the dentate gyrus and impaired context discrimination in adult Fmr1 knockout mice. Hippocampus 2010.
20. El Idrissi A, Ding XH, Scalia J, Trenkner E, Brown WT, Dobkin C. Decreased GABA(A) receptor expression in the seizure-prone fragile X mouse. Neurosci Lett 2005;377:141-6. (Pubitemid 40332346)
21. Erickson CA, Posey DJ, Stigler KA, Mullett J, Katschke AR, McDougle CJ. A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology 2007;191:141-7. (Pubitemid 46294942)
22. Etherton MR, Blaiss CA, Powell CM, Sudhof TC. Mouse neurexin-1 alpha deletion causes correlated electrophysiological and behavioral changes consistent with cognitive impairments. Proc Natl Acad Sci USA 2009;106:17998-8003.
23. Feyder M, Karlsson RM, Mathur P, Lyman M, Bock R, Momenan R, et al. Association of mouse Dlg4 (PSD-95) gene deletion and human DLG4 gene variation with phenotypes relevant to autism spectrum disorders and Williams' Syndrome. Am J Psychiatry 2010;167:1508-17.
24. Fisahn A, Contractor A, Traub RD, Buhl EH, Heinemann SF, McBain CJ. Distinct roles for the kainate receptor subunits GluR5 and GluR6 in kainate-induced hippocampal gamma oscillations. J Neurosci 2004;24:9658-68. (Pubitemid 39441520)
25. Fisahn A, Heinemann SF, McBain CJ. The kainate receptor subunit GluR6 mediates metabotropic regulation of the slow and medium AHP currents in mouse hippocampal neurones. J Physiol 2005;562:199-203. (Pubitemid 40207796)
26. Fries P, Nikolic D, Singer W. The gamma cycle. Trends Neurosci 2007;30:309-16. (Pubitemid 46991120)
27. Gandal MJ, Edgar JC, Ehrlichman RS, Mehta M, Roberts TP, Siegel SJ. Validating gamma oscillations and delayed auditory responses as translational biomarkers of autism. Biol Psychiatry 2010;68:1100-6.
28. Guo W, Wei F, Zou S, Robbins MT, Sugiyo S, Ikeda T, et al. Group I metabotropic glutamate receptor NMDA receptor coupling and signaling cascade mediate spinal dorsal horn NMDA receptor 2B tyrosine phosphorylation associated with inflammatory hyperalgesia. J Neurosci 2004;24:9161-73. (Pubitemid 39372260)
29. Guy J, Hendrich B, Holmes M, Martin JE, Bird A. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet 2001;27:322-6. (Pubitemid 32201856)
30. Holt R, Barnby G, Maestrini E, Bacchelli E, Brocklebank D, Sousa I, et al. Linkage and candidate gene studies of autism spectrum disorders in European populations. Eur J Hum Genet 2010;18:1013-9.
31. Hung AY, Futai K, Sala C, Valtschanoff JG, Ryu J, Woodworth MA, et al. Smaller dendritic spines, weaker synaptic transmission, but enhanced spatial learning in mice lacking Shank1. J Neurosci 2008;28:1697-708. (Pubitemid 351287038)
32. Jamain S, Betancur C, Quach H, Philippe A, Fellous M, Giros B, et al. Linkage and association of the glutamate receptor 6 gene with autism. Mol Psychiatry 2002;7:302-10. (Pubitemid 34280638)
33. Kaytor MD, Orr HT. RNA targets of the fragile X protein. Cell 2001;107:555-7. (Pubitemid 34014856)
34. Kim SA, Kim JH, Park M, Cho IH, Yoo HJ. Family-based association study between GRIK2 polymorphisms and autism spectrum disorders in the Korean trios. Neurosci Res 2007;58:332-5. (Pubitemid 47042267)
35. King BH, Wright DM, Handen BL, Sikich L, Zimmerman AW, McMahon W, et al. Double-blind, placebo-controlled study ofamantadine hydrochloride inthe treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry 2001;40:658-65. (Pubitemid 32473379)
36. Kolozsi E, Mackenzie RN, Roullet FI, deCatanzaro D, Foster JA. Prenatal exposure to valproic acid leads to reduced expression of synaptic adhesion molecule neuroligin 3 in mice. Neuroscience 2009;163:1201-10.
37. Korff S, Harvey BH. Animal models of obsessive-compulsive disorder: rationale to understanding psychobiology and pharmacology. Psychiatr Clin North Am 2006;29:371-90. (Pubitemid 44294451)
38. Kullmann DM, Lamsa K. Roles of distinct glutamate receptors in induction of anti-Hebbian long-term potentiation. J Physiol 2008;586:1481-6. (Pubitemid 351404952)
39. Lauterborn JC, Lynch G, Vanderklish P, Arai A, Gall CM. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J Neurosci 2000;20:8-21. (Pubitemid 30220486)
40. Lodge D. The history of the pharmacology and cloning of ionotropic glutamate receptors and the development of idiosyncratic nomenclature. Neuropharmacology 2009;56:6-21.
41. Maliszewska-Cyna E, Bawa D, Eubanks JH. Diminished prevalence but preserved synaptic distribution of N-methyl-D-aspartate receptor subunits in the methyl CpG binding protein 2(MeCP2)-null mouse brain. Neuroscience 2010;168:624-32.
42. Malkesman O, Scattoni ML, Paredes D, Tragon T, Pearson B, Shaltiel G, et al. The female urine sniffing test: a novel approach for assessing reward-seeking behavior in rodents. Biol Psychiatry 2010;67:864-71.
43. McBride SM, Choi CH, Wang Y, Liebelt D, Braunstein E, Ferreiro D, et al. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 2005;45:753-64. (Pubitemid 40320709)
44. McFarlane HG, Kusek GK, Yang M, Phoenix JL, Bolivar VJ, Crawley JN. Autism-like behavioral phenotypes in BTBR T+tf/J mice. Genes Brain Behav 2008;7:152-63. (Pubitemid 351342192)
45. McNaughton CH, Moon J, Strawderman MS, Maclean KN, Evans J, Strupp BJ. Evidence for social anxiety and impaired social cognition in a mouse model of fragile X syndrome. Behav Neurosci 2008;122:293-300. (Pubitemid 351672321)
46. Meredith RM, de Jong R, Mansvelder HD. Functional rescue of excitatory synaptic transmission in the developing hippocampus in Fmr1-KO mouse. Neurobiol Dis 2010;41:104-10.
47. Mineur YS, Huynh LX, Crusio WE. Social behavior deficits in the Fmr1 mutant mouse. Behav Brain Res 2006;168:172-5. (Pubitemid 43152066)
48. Morales J, Hiesinger PR, Schroeder AJ, Kume K, Verstreken P, Jackson FR, et al. Drosophila fragile X protein, DFXR, regulates neuronal morphology and function in the brain. Neuron 2002;34:961-72. (Pubitemid 34722285)
49. Moy SS, Nadler JJ, Poe MD, Nonneman RJ, Young NB, Koller BH, et al. Development of a mouse test for repetitive, restricted behaviors: relevance to autism. Behav Brain Res 2008;188:178-94.
50. Musumeci SA, Calabrese G, Bonaccorso CM, D'Antoni S, Brouwer JR, Bakker CE, et al. Audiogenic seizure susceptibility is reduced in fragile X knockout mice after introduction of FMR1 transgenes. Exp Neurol 2007;203:233-40. (Pubitemid 44830027)
51. Nakamoto M, Nalavadi V, Epstein MP, Narayanan U, Bassell GJ, Warren ST. Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors. Proc Natl Acad Sci USA 2007;104:15537-42. (Pubitemid 47502952)
52. Niederhofer H. Glutamate antagonists seem to be slightly effective in psychopharmacologic treatment of autism. J Clin Psychopharmacol 2007;27:317-8. (Pubitemid 46763326)
53. Orekhova EV, Stroganova TA, Nygren G, Tsetlin MM, Posikera IN, Gillberg C, et al. Excess of high frequency electroencephalogram oscillations in boys with autism. Biol Psychiatry 2007;62:1022-9. (Pubitemid 47562364)
54. Polleux F, Lauder JM. Toward a developmental neurobiology of autism. Ment Retard Dev Disabil Res Rev 2004;10:303-17. (Pubitemid 40209463)
55. Purcell AE, Jeon OH, Zimmerman AW, Blue ME, Pevsner J. Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology 2001;57:1618-28. (Pubitemid 33055480)
56. Ramsey AJ. NR1 knockdown mice as a representative model of the glutamate hypothesis of schizophrenia. Prog Brain Res 2009;179:51-8.
57. Rinaldi T, Kulangara K, Antoniello K, Markram H. Elevated NMDA receptor levels and enhanced postsynaptic long-term potentiation induced by prenatal exposure to valproic acid. Proc Natl Acad Sci USA 2007;104:13501-6. (Pubitemid 47293974)
58. Rodriguez-Moreno A, Sihra TS. Metabotropic actions of kainate receptors in the CNS. J Neurochem 2007;103:2121-35. (Pubitemid 350173562)
59. Rojas DC, Maharajh K, Teale P, Rogers SJ. Reduced neural synchronization of gamma-band MEG oscillations in first-degree relatives of children with autism. BMC Psychiatry 2008;8:66.
60. Santos M, Silva-Fernandes A, Oliveira P, Sousa N, Maciel P. Evidence for abnormal early development in a mouse model of Rett syndrome. Genes Brain Behav 2007;6:277-86. (Pubitemid 46587988)
61. Schneider T, Przewlocki R. Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacology 2005;30:80-9. (Pubitemid 40024402)
62. Shaltiel G, Maeng S, Malkesman O, Pearson B, Schloesser RJ, Tragon T, et al. Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania. Mol Psychiatry 2008;13:858-72.
63. Shuang M, Liu J, Jia MX, Yang JZ, Wu SP, Gong XH, et al. Family-based association study between autism and glutamate receptor 6 gene in Chinese Han trios. Am J Med Genet B Neuropsychiatr Genet 2004;131B:48-50. (Pubitemid 39458437)
64. Silverman JL, Tolu SS, Barkan CL, Crawley JN. Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP. Neuropsychopharmacology 2010a;35:976-89.
65. Silverman JL, Turner SM, Barkan CL, Tolu SS, Saxena R, Hung AY, et al. Sociability and motor functions in Shank1 mutant mice. Brain Res 2010b.
66. Simonyi A, Schachtman TR, Christoffersen GR. The role of metabotropic glutamate receptor 5 in learning and memory processes. Drug News Perspect 2005;18:353-61. (Pubitemid 43073869)
67. Spencer CM, Graham DF, Yuva-Paylor LA, Nelson DL, Paylor R. Social behavior in Fmr1 knockout mice carrying a human FMR1 transgene. Behav Neurosci 2008;122:710-5. (Pubitemid 351787849)
68. Spires TL, Molnar Z, Kind PC, Cordery PM, Upton AL, Blakemore C, et al. Activitydependent regulation of synapse and dendritic spine morphology in developing barrel cortex requires phospholipase C-beta1 signalling. Cereb Cortex 2005;15:385-93. (Pubitemid 40388239)
69. Strutz-Seebohm N, Korniychuk G, Schwarz R, Baltaev R, Ureche ON, Mack AF, et al. Functional significance of the kainate receptor GluR6(M836I) mutation that is linked to autism. Cell Physiol Biochem 2006;18:287-94. (Pubitemid 44946983)
70. Suvrathan A, Hoeffer CA, Wong H, Klann E, Chattarji S. Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome. Proc Natl Acad Sci USA 2010;107:11591-6.
71. Svitkina T, Lin WH, Webb DJ, Yasuda R, Wayman GA, Van Aelst L, Soderling SH. Regulation of the postsynaptic cytoskeleton: roles in development, plasticity, and disorders. J Neurosci 2010;30:14937-42.
72. Tu JC, Xiao B, Naisbitt S, Yuan JP, Petralia RS, Brakeman P, et al. Coupling of mGluR/ Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron 1999;23:583-92. (Pubitemid 29359928)
73. Tucker B, Richards RI, Lardelli M. Contribution of mGluR and Fmr1 functional pathways to neurite morphogenesis, craniofacial development and fragile X syndrome. Hum Mol Genet 2006;15:3446-58. (Pubitemid 44811597)
74. Uhlhaas PJ, Singer W. Abnormal neural oscillations and synchrony in schizophrenia. Nat Rev 2010;11:100-13.
75. Wan L, Dockendorff TC, Jongens TA, Dreyfuss G. Characterization of dFMR1, a Drosophila melanogaster homolog of the fragile X mental retardation protein. Mol Cell Biol 2000;20:8536-47.
76. Westmark CJ, Westmark PR, Malter JS. MPEP reduces seizure severity in Fmr-1 KO mice over expressing human Abeta. Int J Clin Exp Pathol 2009;3:56-68.
77. Wilson TW, Rojas DC, Reite ML, Teale PD, Rogers SJ. Children and adolescents with autism exhibit reduced MEG steady-state gamma responses. Biol Psychiatry 2007;62:192-7. (Pubitemid 47042016)
78. Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev 2005;11:169-82. (Pubitemid 41278980)
79. Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP. Suppression of two major fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 2005;49:1053-66. (Pubitemid 41503304)
80. Zoghbi HY. Postnatal neurodevelopmental disorders: meeting at the synapse? Science 2003;302:826-30. (Pubitemid 37339616)